Best Cardiac and Vascular Disorders Companies in United States
The 1315 best Cardiac and Vascular Disorders companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
Ranked by disclosed equity funding and funding momentum, this directory captures 1,315 Cardiac and Vascular Disorders companies across the United States, representing $26.5 billion in total disclosed capital. The scale here is real. Nineteen validated filers report a combined revenue pool of roughly $2.7 billion, with a median revenue of $9 million growing at 9% year-over-year. But the outsized earners pull that pool hard: Edwards Lifesciences Corp booked $1.6 billion in revenue at 17% growth, and its $381 million net income sits at 44 times the sector median. Shockwave Medical posted $219 million at a sharp 36% clip, clearing $55 million in net income, or 6 times that same median. Kiniksa Pharmaceuticals delivered 56% revenue growth to $214 million. These aren't projections, they're filed figures.
On the funding side, Imperative Care leads at $496 million raised, with Impulse Dynamics close behind at $443 million and Corxel at $287 million. So if you're mapping capital concentration, those three names are your anchors. Government-backed investors including HHS, NIH, and the National Science Foundation dominate the active investor list, which tells you something about where early-stage bets are coming from. As shown in 2011 research, cardiovascular intervention outcomes carry long-term systemic cost implications, which partly explains why public capital keeps flowing into this space. I'd watch the cardiovascular hospital and prostate cancer adjacencies, both flagged as rising themes across current coverage.
Ranked: Best Cardiac and Vascular Disorders companies in United States
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Imperative Care Provider of access catheters for cardiovascular diagnosis and treatment 82Funding top 14%Patents top 15%Innovation top 18%Moat top 26% All 10 signals ▾Fundingtop 14% Patentstop 15% Innovationtop 18% Moattop 26% Growthtop 27% Techtop 36% Talenttop 38% Markettop 48% Newsbottom 48% Globalbottom 42% Funding: Raised $496M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Patents: 261 patents matched (strict assignee match) · 225 filings since 2022 vs 36 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $496M | 3 mo ago | Series E | 90 | Dr Hopkins Co-founder | 4 signals ▼33% Funding | 261 patents Robotic-assisted neurovascular catheter systems for precise multi‑catheter interventions | — |
| 2 | Impulse Dynamics Provider of implantable device for treatment of chronic heart failure 40Funding top 13%Moat top 31%Product top 34%Tech top 49% All 10 signals ▾Fundingtop 13% Moattop 31% Producttop 34% Techtop 49% Patentsbottom 49% Globalbottom 46% Innovationbottom 45% Marketbottom 41% Growthbottom 38% Newsbottom 27% Funding: Raised $443M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $443M | 6 mo ago | Series F | 36 | — | — | 18 patents Implantable cardiac muscle stimulation devices and protein‑based therapeutic modulation. | — |
| 3 | CORXEL Developer of therapies for patients with cardiometabolic conditions | $287M | 4 mo ago | Series D | — | Sandy Mou CEO | — | — | — |
| 4 | Ablative Solutions Developer of renal denervation for treatment of hypertension | $260M | 7 mo ago | Series D | 24 | — | — | 173 patents Patents concentrated in health & consumer products | — |
| 5 | Tenaya Therapeutics Developer of regenerative and gene therapeutics for heart failure | $248M | 16 mo ago | Public | 141 141 → 93 (-34%) · sector median +22% | Benoit Bruneau Co-Founder | — | 207 patents Engineered AAV capsids and CRISPR guides for cardiac gene‑therapy targeting PLN mutations | — |
| 6 | Rivus Pharmaceuticals Developer of therapeutics for cardio-metabolic disorders | $233M | 17 mo ago | Series B | 12 | Allen Cunningham CEO | — | — | 1 launch |
| 7 | Cardiac Dimensions Developer of invasive cardiac implants for heart failure | $208M | 14 mo ago | Series E | 31 31 → 73 (+135%) · sector median +22% | — | — | 154 patents Recapturable cardiac valve repair devices and modular implant delivery systems | — |
| 8 | Orchestra BioMed Developer of medical devices for hypertension and atherosclerosis treatment | $206M | 10 mo ago | Public | 47 | Darren Sherman President | 12 signals ▲300% Announcements · Capital raise · Earnings | — | 1 partnership |
| 9 | Braveheart Developer of a treatment for hypertrophic cardiomyopathy and related conditions | $185M | 7 mo ago | Series A | — | Travis Murdoch CEO & President | — | — | — |
| 10 | Bioventrix Ventricle reshaping device 40Funding top 16%Moat top 19%Patents top 36%Talent top 38% All 9 signals ▾Fundingtop 16% Moattop 19% Patentstop 36% Talenttop 38% Innovationtop 43% Globalbottom 45% Techbottom 36% Marketbottom 30% Newsbottom 27% Funding: Raised $181M across 25 rounds · 25 rounds over 22 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 185 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $181M | 2 mo ago | Series E | 20 20 → 23 (+15%) · sector median +22% | Lon Annest Co-Founder | — | 185 patents Percutaneous cardiac implant and monitoring systems for heart failure treatment | — |
| 11 | Eko Provider of AI-based remote patient monitoring platform for cardiac health 72Funding top 16%Customers top 22%Tech top 25%Product top 30% All 11 signals ▾Fundingtop 16% Customerstop 22% Techtop 25% Producttop 30% Moattop 31% Talenttop 43% AItop 45% Markettop 48% Globalbottom 45% Growthbottom 44% Newsbottom 20% Funding: Raised $167M across 16 rounds · 16 rounds over 11 yrs (1.5/yr) Customers: Play-Store rating 4.81★ across 4,901 ratings (2 apps) · Review volume +17% in 6 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $167M | 14 mo ago | Series D | 95 95 → 204 (+115%) · sector median +22% | Jason Bellet Co-Founder | — | — | 1 launch |
| 12 | Vital Connect Developer of biosensor patch for body vitals monitoring 64Product top 18%Funding top 21%Moat top 26%Patents top 32% All 11 signals ▾Producttop 18% Fundingtop 21% Moattop 26% Patentstop 32% Talenttop 34% Innovationtop 36% Growthtop 43% Techtop 45% Markettop 49% Globalbottom 47% Newsbottom 18% Product: 6 distinct product lines · Company stage: Series G Funding: Raised $140M across 8 rounds · 8 rounds over 15 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $140M | 15 mo ago | Series G | 184 184 → 199 (+8%) · sector median +22% | Nersi Nazari Founder | — | 239 patents Wearable biosensor systems for continuous cardiovascular and vital‑sign monitoring | — |
| 13 | Anteristech Provider of technologies for developing heart valve | $126M | 7 mo ago | Public | 27 | — | 14 signals ▲100% Funding · Capital raise · IPO | — | — |
| 14 | Supira Medical Developer of ventricular assist devices for coronary intervention and cardiogenic shock | $120M | 14 mo ago | Series E | 78 | — | — | — | 3 launchs |
| 15 | EnChannel Medical Developer of medical device for cardiac disorders | $110M | 13 mo ago | Series B | — | Graydon Beatty Co-Founder | — | — | — |
| 16 | Galvanize Developer of pulsed electric field systems for various medical indications | $110M | 11 mo ago | Series C | 114 | Jonathan Waldstreicher Founder & CEO | 8 signals Funding · Leadership · New product | — | — |
| 17 | Neochord Provider of minimally -invasive devise for valve repair | $108M | 15 mo ago | Series E | 7 | David Chung President & CEO | — | 142 patents Minimally invasive cardiac valve repair devices and suture anchoring technologies | — |
| 18 | Corvia Medical Developer of transcatheterally shunt for treating diastolic heart failure disease | $105M | 12 mo ago | Acquired | 32 32 → 38 (+19%) · sector median +22% | George Fazio President & CEO | — | — | — |
| 19 | Alleviant Medical Developer of devices to lift the burden of heart failure | $89M | 15 mo ago | Series C | 37 | Jacob Kriegel Md Co-Founder & CMO | — | — | — |
| 20 | Field Medical Developer of device for the treatment of heart arrhythmia conditions | $89M | 11 mo ago | Series B | 352 | Steven Mickelsen Founder & CTO | — | — | 1 expansion |
| 21 | 4C Medical Developer of medical devices for the treatment of mitral regurgitation | $88M | 15 mo ago | Series D | 28 | Jeffrey Chambers Founder | — | 547 patents Minimally invasive electrosurgical instruments and RF‑activated surgical systems for laparoscopy | — |
| 22 | Reprieve Cardiovascular Developer of decongestion management solution for acute decompensated heart failure patients | $84M | 10 mo ago | Series B | 16 | — | — | 61 patents Non‑invasive urine output monitoring and personalized fluid therapy for heart failure patients | — |
| 23 | BioIntelliSense Developer of medical-grade wearable devices and data services for patient monitoring 50Funding top 21%Moat top 21%Patents top 25%Innovation top 26% All 10 signals ▾Fundingtop 21% Moattop 21% Patentstop 25% Innovationtop 26% Producttop 35% Talenttop 38% Techbottom 49% Globalbottom 40% Marketbottom 36% Customersbottom 3% Funding: Raised $82.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 47 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $82M | 6 mo ago | Series C | 26 | James Mault Co-Founder&CEO | — | 47 patents Wearable multi-parameter physiological monitoring and biosensing devices | — |
| 24 | Corsera Health Developer of technology predicting and preventing cardiovascular disease before it begins 72Funding top 24%Talent top 28%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 24% Talenttop 28% AItop 45% Globalbottom 48% Funding: Raised $80.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $80M | 5 mo ago | Series A | — | Chris Cox Co-Founder | — | — | — |
| 25 | Tioga Cardiovascular Developer of valve replacement solutions | $75M | 9 mo ago | Series C | 53 | Amr Salahieh Co-Founder | — | — | — |
| 26 | Adagio Medical Stealth mode startup developing cardiovascular therapies | $72M | 8 mo ago | Public | 72 72 → 52 (-28%) · sector median +22% | Olav Bergheim Founder | 3 signals ▼75% Funding | 158 patents Catheter-based cryoablation systems with conductive liners and shape‑memory steering. | 5 job openings |
| 27 | Polares Medical Developer of medical devices for treating mitral valve regurgitation | $65M | 3 mo ago | Series C | 20 | Jacques Essinger Founder & CEO | 3 signals Funding · Capital raise | — | — |
| 28 | Instylla Developer of hydrogel technology for embolization therapy | $64M | 11 mo ago | Series B | 26 | — | — | — | 2 launchs |
| 29 | AtaCor Medical Transforming cardiac rhythm management with innovative extravascular pacing and defibrillation solutions | $62M | 8 mo ago | Series D | 15 15 → 33 (+120%) · sector median +22% | Alan Marcovecchio Co-Founder & VP Clinical | — | 146 patents Implantable cardiac pacing lead delivery, sensing, and control technologies | — |
| 30 | Ionetix Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy | $61M | 3 mo ago | Series C | 50 | Kevin Cameron CEO | — | 9 patents Compact superconducting cyclotron systems for medical and research particle acceleration | 3 job openings |
| 31 | Mezzion Developer of medicine for single ventricle heart disease | $60M | 12 mo ago | Public | 10 | Dean Park Founder & CEO | — | — | — |
| 32 | Shape Memory Medical Developer of embolization devices based on Shape Memory Polymer material | $57M | 14 mo ago | Series C | 37 37 → 46 (+24%) · sector median +22% | Edward Ruppel CEO & President | — | — | — |
| 33 | Aronora Developing first-in-class biologics for life-threatening blood diseases with unmet needs | $55M | 9 mo ago | Seed | 8 | Erik Tucker President & CEO | — | 45 patents Antibody-based anticoagulant therapeutics targeting coagulation factors XI, XII, thrombin, and thrombopoietin. | — |
| 34 | Okami Medical Developer of innovative, versatile, and intuitive medical devices for peripheral vessels treatment | $55M | 6 mo ago | Series F | 8 | Paul Lubock Co-Founder | 5 signals ▲400% Funding | — | 2 launchs |
| 35 | Cagent Vascular Developer of a device for removal of vascular blockages 57Moat top 21%Funding top 24%Patents top 30%Innovation top 31% All 9 signals ▾Moattop 21% Fundingtop 24% Patentstop 30% Innovationtop 31% Techtop 34% Talentbottom 49% Globalbottom 45% Marketbottom 39% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 117 patents Funding: Raised $54.4M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $54M | 1 mo ago | Series D | 40 | Robert Giasolli Founder | — | 117 patents Drug‑eluting serrated balloon catheters for precise intravascular drug delivery | 1 launch |
| 36 | Peerbridge Health Developer of ambulatory ECG system with AI-enabled cardiac diagnostics 42Innovation top 23%Funding top 27%Product top 30%Moat top 39% All 7 signals ▾Innovationtop 23% Fundingtop 27% Producttop 30% Moattop 39% Techtop 48% Globalbottom 37% Marketbottom 19% Innovation: 4 product lines · Deep-tech classification: Tech Hardware Funding: Raised $46.1M across 14 rounds · 14 rounds over 11 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $46M | 13 mo ago | Series B | 3 | — | — | — | 1 launch · 1 expansion |
| 37 | Aria CV Device for pulmonary hypertension | $44M | 10 mo ago | Series B | 17 | Dan Gladney Chief Executive Officer | — | 59 patents Implantable cardiovascular pressure-regulating devices for pulmonary hypertension treatment | — |
| 38 | InspireMD Stents integrated with a bio-stable mesh | $34M | 10 mo ago | Public | 66 66 → 121 (+83%) · sector median +22% | — | 3 signals ▼70% Earnings · Contracts | — | — |
| 39 | LifeLens Developer of wireless ECG monitor for personal health monitoring use 37Talent top 28%Funding top 32%Product top 35%Moat top 38% All 9 signals ▾Talenttop 28% Fundingtop 32% Producttop 35% Moattop 38% Techbottom 48% Innovationbottom 47% Marketbottom 34% Patentsbottom 32% Globalbottom 31% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $24.6M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $25M | 7 mo ago | Series B | 45 | David Robins Co-Founder | — | 5 patents Patents concentrated in health & consumer products | — |
| 40 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | Series A | 8 | Sudhish Sharma Co-Founder | — | — | — |
| 41 | Jupiter Endovascular Developer of minimally invasive medical devices for endovascular intervention | $21M | 8 mo ago | Series B | — | Carl St Bernard Chief Executive Officer | — | — | — |
| 42 | SOLEY Therapeutics Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke | $20M | 5 mo ago | Series C | 10 | Yerem Yeghiazarians Co-Founder & CEO | — | — | 1 job opening · 1 launch |
| 43 | Centese Developer of a surgical drainage system | $18M | 0 mo ago | Series B | 13 | Evan Luxon Co-Founder & CEO | — | 25 patents Negative-pressure chest and wound drainage systems for thoracic surgery | 2 launchs |
| 44 | Thrombolex Developer of endovascular catheters for acute venous thromboembolic conditions | $18M | 3 mo ago | Series A | 18 | — | — | 41 patents Interventional catheter baskets for embolic removal and infusion drug delivery | 3 launchs |
| 45 | Venturemed Group Developer of endovascular devices for the treatment of PAD and stenoses of AV fistulas and grafts | $16M | 8 mo ago | Series C | 15 | Denis Harrington President & CEO | 3 signals Leadership · Funding | 36 patents Advanced intravascular catheters with expandable, incising, drug‑delivery and embolic protection features | — |
| 46 | VisCardia Developer of implantable medical therapy for the treatment of heart failure | $16M | 8 mo ago | Series C | 5 | — | — | 70 patents Implantable diaphragmatic stimulation systems for cardiac and respiratory therapeutic support | — |
| 47 | Micro Medical Solutions Developer of a device for CLI and PAD patients to prevent amputation | $13M | 7 mo ago | Series B | 13 | Gregory Sullivan Co-Founder & CEO | — | — | — |
| 48 | Piraeus Medical Developer of solutions for stroke thrombectomy procedures | $11M | 2 mo ago | Series B | — | Jared Hutar Chief Executive Officer | — | — | — |
| 49 | Sonovascular eveloper of a medical device to treat arterial and venous diseases | $8M | 4 mo ago | Series A | 8 | Daniel Estay Founder & CEO | — | 7 patents Intravascular ultrasound catheter technology for enhanced imaging and therapeutic delivery. | — |
| 50 | Cloud Provider of cloud-based remote cardiology vital signs monitoring devices and platforms 67Growth top 21%Innovation top 22%Patents top 23%Moat top 32% All 11 signals ▾Growthtop 21% Innovationtop 22% Patentstop 23% Moattop 32% Fundingtop 35% Fin. healthtop 38% Producttop 39% Techbottom 48% Globalbottom 46% Newsbottom 40% Marketbottom 37% Growth: Revenue +701% YoY · Fresh capital in last 24 mo Innovation: 85 patents (top 21% of patent-holders) · 23 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $3M | 2 mo ago | Public | 55 | — | — | 85 patents Remote health monitoring, biomedical AR, and networked fax/telemedicine data transmission | — |
Top 12 Cardiac and Vascular Disorders companies in United States
#1
Series E · Campbell, California · founded 2015 · 90 employees$496Mraised▾
Provider of access catheters for cardiovascular diagnosis and treatment. The catheters are used in deep navigation into the blood vessels of the brain to prevent strokes. The flagship product ZOOM Aspiration System is a family of products designed to facilitate clot removal during ischemic stroke.
- Mar 2026Series E$100M
- Jul 2024Series E$150M
- Jul 2021Series D$260M
- Dec 2019Series C$86M
#2
Series E · San Ramon, California · founded 2003 · 20 employees$181.4Mraised▾
BioVentrix develops clinical solutions for treating heart failure patients. It provides PliCath HF, an epicardial catheter-based ventricular reconstruction device. Product is not commercially available.
- Apr 2026Series E$705K
- Oct 2024Series E$6.7M
- Mar 2024Series E$3.6M
- Apr 2023Series E$48.5M
#3
Series F · Marlton, New Jersey · founded 1998 · 36 employees$443.1Mraised▾
Impulse Dynamics is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed, Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer is CE is FDA approved.
- Dec 2025Series F$158M
- Feb 2025Unattributed$84.1M
- Feb 2024Series E$136.5M
- Jul 2023Series E$91.4M
#4
Series D · Wayne, Pennsylvania · founded 2014 · 40 employees$54.4Mraised▾
Developer of a device for removal of vascular blockages. The company is developing a Lesion Preparation balloon designed to enable more effective removal of blockages in blood vessels and to increase drug uptake when used along with a Drug-Coated Balloon. Their technology has applications in the treatment of Peripheral arterial disease.
- May 2026Series D$41M
- Feb 2025Series C$15M
- Jan 2024Series C$30M
- Jun 2021Series B$9.5M
#5
Series D · Berkeley Heights, New Jersey · founded 2019$287Mraised▾
Developer of therapies for patients with cardiometabolic conditions. It offers a pipeline of treatments including an oral small molecule GLP-1 receptor agonist for the treatment of obesity and diabetes mellitus, JX10 is an investigational drug for acute ischemic stroke, and JX09 a next-generation highly selective aldosterone synthase inhibitor for hypertension, heart failure and chronic kidney disease.
- Jan 2026Series D$287M
#6
Series D · Kalamazoo, Michigan · founded 2011 · 24 employees$259.6Mraised▾
Developer of renal denervation for treatment of hypertension. The company has developed a catheter-based approach for the delivery of diagnostic and therapeutic agents into the area surrounding the peripheral blood vessels. The Peregrine renal denervation system is being evaluated for treating hypertension.
- Nov 2025Series D$10.4M
- Dec 2024Series D$37.2M
- Mar 2023Series D$29.3M
- Jun 2022Series D$91.4M
#7
Series C · Palo Alto, California · founded 2010 · 20 employees$65Mraised▾
Developer of medical devices for treating mitral valve regurgitation. The company is developing a minimally-invasive trans-catheter hemi-replacement system, PLAR system, to treat insufficiency in the function of the mitral valve.
- Mar 2026Series C$50M
- Jun 2020Series B$40M
- Jul 2018Series A$25M
#8
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
#9
Series C · San Francisco, California · founded 2009 · 50 employees$61.1Mraised▾
Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy. The company provides full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. It developed a compact superconducting cyclotron used to produce N-13 Ammonia, a PET imaging agent. The company establishes a network of cyclotrons installed near PET programs, making this tracer accessible and affordable. It supports the development and commercialization of targeted alpha therapy (TAT), an emerging cancer therapy utilizing alpha radionuclides. The company is committed to the design, manufacturing, and support of safe and effective radiopharmaceutical products. It offers a turnkey solution eliminating the expense of launching a Cardiac PET program. The company fosters scientific partnerships and sponsorships to deliver advanced radiopharmaceuticals, providing access to scarce diagnostics and therapeutic radiopharmaceuticals.
- Feb 2026Post IPO$30M
- Aug 2024Series C—
- May 2020Series C$37.3M
- Mar 2018Series B$23.8M
#10
Series A · San Francisco, California · founded 2025$185Mraised▾
Developer of a treatment for hypertrophic cardiomyopathy and related conditions. It focuses on addressing the underlying mechanisms of the condition to improve heart performance. The company is advancing its investigational treatment through late-stage clinical development. Hypertrophic cardiomyopathy causes the heart muscle to become abnormally thick, particularly in the left ventricle.
- Nov 2025Series A$185M
#11
Public · Eagan, Minnesota · founded 2006 · 27 employees$126.2Mraised▾
Provider of technologies for developing heart valve. The company has developed a 3D single-piece aortic valve called the DurAVR heart valve that uses its patented ADAPT technology. The other products developed are DurAVR leaflet repair (RP), DurAVR transcatheter heart valve (THV), DurAVR surgical heart valve (SHV).
- Oct 2025Post IPO$11.5M
- Apr 2024Post IPO$15.2M
- Mar 2022Post IPO$20M
- Oct 2021Post IPO$3.8M
#12
Series B · Omaha, Nebraska · founded 2016 · 13 employees$17.9Mraised▾
Developer of a surgical drainage system. The Thoraguard is integrated with a software to notify the clinical staff for any leakages through an alarm. The system is integrated with sensors and software offers automated management for suction and tracks the drainage output rates. The system also has clog-free chest tubes.
- May 2025Series B$525K
- May 2025Conventional Debt—
- Nov 2023Series B$15M
- Nov 2017Seed$2.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.